nVerses Capital LLC Invests $56,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

nVerses Capital LLC acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,500 shares of the company’s stock, valued at approximately $56,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Vir Biotechnology by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 12,297,139 shares of the company’s stock valued at $123,709,000 after purchasing an additional 1,096,473 shares during the last quarter. Millennium Management LLC raised its holdings in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after buying an additional 606,804 shares during the period. Federated Hermes Inc. lifted its position in Vir Biotechnology by 19,327.1% in the second quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock valued at $2,671,000 after buying an additional 298,603 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in Vir Biotechnology during the second quarter worth about $1,780,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Vir Biotechnology by 6,402.0% during the second quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock valued at $1,679,000 after acquiring an additional 185,723 shares during the last quarter. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on VIR shares. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Barclays raised their price target on Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.80.

Vir Biotechnology Stock Up 0.3 %

Vir Biotechnology stock opened at $7.65 on Tuesday. Vir Biotechnology, Inc. has a 52-week low of $7.12 and a 52-week high of $13.09. The firm has a market cap of $1.05 billion, a PE ratio of -2.14 and a beta of 0.46. The company’s 50 day moving average is $7.91 and its two-hundred day moving average is $8.95.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. During the same period in the prior year, the company posted ($1.45) EPS. The firm’s revenue was down 19.0% compared to the same quarter last year. On average, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the sale, the director now directly owns 11,616 shares in the company, valued at approximately $90,604.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.60% of the stock is owned by corporate insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).